Article Text

Download PDFPDF
Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial
  1. N Putschky1,
  2. H-G Pott1,
  3. J G Kuipers2,
  4. H Zeidler3,
  5. M Hammer4,
  6. J Wollenhaupt5
  1. 1Rheumatologikum Hannover, Hannover, Germany
  2. 2Division of Rheumatology, Red Cross Hospital, Bremen, Germany
  3. 3Division of Rheumatology, Medical School Hannover, Hannover, Germany
  4. 4Division of Rheumatology, St Josef-Stift, Sendenhorst, Germany
  5. 5Division of Rheumatology, General Hospital Eilbeck, Hamburg, Germany
  1. Correspondence to:
    N Putschky
    Rheumatologikum Hannover, Rathenaustr 13/14, 30159 Hannover, Germany; service{at}


Objective: To compare the efficacy of a 10-day and a 4-month doxycylcine course for the treatment of Chlamydia trachomatis-reactive arthritis (Ct-ReA).

Methods: Patients with active Ct-ReA were enrolled in a prospective, multicentre, double-blind, controlled clinical trial and randomised to receive doxycycline 100 mg twice daily for 10 days followed either by placebo or by continued doxycycline 100 mg twice daily over 4 months. Various clinical and laboratory parameters referring to disease activity were recorded in the beginning and at the end of treatment.

Results: 32 of 37 patients included (15 men and 17 women; mean (standard deviation) disease duration 17 (13) months completed the study; 17 were randomised to short-term doxycycline and placebo (placebo group) and 15 to prolonged treatment with doxycycline (doxycycline group) over the 4-month study period. After this time, only two patients from each group went into remission. There were no drop-outs owing to adverse events or treatment failures.

Conclusions: The results of this study suggest that prolonged treatment with a 4-month course of doxycycline is not superior to short-term treatment over 10 days in patients with Ct-ReA.

  • Ct-ReA, Chlamydia trachomatis-reactive arthritis
  • ESR, erythrocyte sedimentation rate

Statistics from


  • Competing interests: None declared.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.